Which peptides show up in muscle-growth research? A full-length reference on the GH/IGF-1 axis, GHSR secretagogues, mitochondrial-derived peptides and repair peptides — with comparison tables and FAQ.
Peptides that appear in muscle-growth and hypertrophy research broadly fall into four mechanistic axes: (1) GHRH analogs that drive endogenous growth-hormone pulsatility, (2) GHSR (ghrelin receptor) secretagogues that amplify GH pulses, (3) direct IGF-1 or IGF-1 analog peptides, and (4) mitochondrial-derived peptides that modulate cellular energy availability. A fifth adjacent category — tissue-repair peptides such as BPC-157 and TB-500 — is typically studied in recovery rather than hypertrophy research but is frequently profiled in parallel.
This reference maps every commonly studied compound to its axis, expected in-vitro / model signalling and the documentation researchers should expect on the COA. All content is research-use-only.
The four mechanistic axes at a glance
| Axis | Representative peptides | Primary receptor / target | Research signalling |
|---|---|---|---|
| GHRH axis | Sermorelin, Tesamorelin, CJC-1295 (±DAC) | GHRH receptor (pituitary) | Endogenous GH pulse amplitude |
| GHSR axis | Ipamorelin, GHRP-2, GHRP-6 | GHSR-1a (ghrelin receptor) | GH pulse frequency; synergy with GHRH |
| IGF-1 axis | IGF-1 LR3, IGF-1 DES | IGF-1 receptor | Downstream anabolic signalling in models |
| Mitochondrial | MOTS-c, Humanin | AMPK, mitochondrial biogenesis | Cellular energy substrate research |
Why GHRH + GHSR peptides are studied together
GHRH analogs (Sermorelin, Tesamorelin, CJC-1295) and GHSR secretagogues (Ipamorelin, GHRP-2) engage independent receptor pathways at the pituitary. In-vitro and animal-model literature reports super-additive GH release when both are engaged simultaneously — the mechanistic rationale for the widely referenced CJC-1295 + Ipamorelin research blend. This synergy is why muscle-research protocols rarely study a GHRH analog in isolation.
GHRH analog reference table
| Peptide | Half-life (research literature) | Distinguishing feature |
|---|---|---|
| Sermorelin | ~10–20 min | GHRH(1–29) truncation; short-acting pulsatile |
| Tesamorelin | ~26 min | Trans-3-hexenoyl N-terminal stabilisation |
| CJC-1295 (no DAC) | ~30 min | Mod-GRF(1–29); no albumin linker |
| CJC-1295 with DAC | ~6–8 days | DAC linker binds serum albumin |
GHSR secretagogue reference table
| Peptide | Selectivity notes |
|---|---|
| Ipamorelin | Highly selective GHSR agonist |
| GHRP-2 | Broader endocrine engagement in models |
| GHRP-6 | Similar to GHRP-2; historical reference tool |
Mitochondrial peptides: MOTS-c and Humanin
Mitochondrial-derived peptides (MDPs) are encoded within mitochondrial DNA reading frames. MOTS-c (16 residues, encoded in the 12S rRNA region) engages AMPK-related metabolic pathways in cultured skeletal muscle cells. It sits outside the GH axis entirely and is used to study cellular energy availability during muscle-research assays.
Adjacent tissue-repair peptides
BPC-157 (VEGFR2 / NO pathway) and TB-500 (actin sequestration) are widely referenced alongside muscle-growth research even though their published mechanisms are tissue-repair rather than hypertrophy. They frequently appear in the same research programs because repair capacity and anabolic signalling are studied in parallel.
Documentation checkpoints for muscle-research peptides
- Batch identifier and synthesis date traceable to the lot record
- HPLC purity ≥98% (typically ≥99% for peptides under 30 residues)
- LC-MS confirmed monoisotopic or average mass within ±0.5 Da of theoretical
- Counterion identity and content (acetate or trifluoroacetate) reported
- Bacterial endotoxin and residual solvents per the analytical method
Which peptides are most cited in muscle-growth research?
The GHRH + GHSR pairing (CJC-1295 + Ipamorelin), the standalone GHRH analogs (Sermorelin, Tesamorelin), IGF-1 analogs (LR3, DES) and MOTS-c dominate the muscle-research literature, with BPC-157 and TB-500 appearing in adjacent repair-focused work.
Why is CJC-1295 + Ipamorelin so commonly studied together?
CJC-1295 (a GHRH analog) and Ipamorelin (a GHSR-1a secretagogue) engage independent receptor pathways at the pituitary. Published in-vitro work reports super-additive GH release when both are engaged simultaneously, which is why the pairing is the reference standard in growth-axis research.
What is the difference between CJC-1295 with and without DAC?
The DAC (Drug Affinity Complex) linker binds serum albumin, extending the reported half-life from roughly 30 minutes (no DAC) to several days (with DAC). No-DAC CJC-1295 preserves the natural GH pulse profile; DAC-CJC-1295 creates a sustained GH-releasing background in research models.
Is MOTS-c a GH-axis peptide?
No. MOTS-c is a mitochondrial-derived peptide encoded within mitochondrial DNA. It engages AMPK-related metabolic pathways rather than the pituitary GH axis, and is studied for cellular energy availability in muscle-research models.
How do BPC-157 and TB-500 fit into muscle research?
They are tissue-repair peptides — BPC-157 acts via VEGFR2 / NO signalling, TB-500 via actin sequestration. They appear in muscle-research programs when repair capacity is being profiled alongside anabolic signalling, not as hypertrophy tools themselves.
What should a muscle-peptide COA include?
HPLC purity ≥98%, mass-spectrometry identity within ±0.5 Da of theoretical, counterion identity (acetate vs TFA), residual solvent testing, endotoxin data and full batch traceability.
